Metropolis Healthcare Reports Strong FY26 Earnings

Metropolis Healthcare Ltd. reported its audited financial results for the fiscal year ending March 31, 2026, showcasing significant year-on-year growth in both revenue and profit.

A second interim dividend of Re 1 per equity share (face value Rs 2) for FY2025-26 was declared, with a record date of May 19, 2026, and payment due within 30 days.

In a key governance move, Deloitte Haskins & Sells Chartered Accountants LLP has been appointed as the new statutory auditors for a five-year term, succeeding BSR & Co. LLP.

Additionally, Dr. Nilesh Shah will transition from his role as President - Internal Assurance to an advisory position, effective May 14, 2026, ceasing to be Senior Management Personnel from May 13, 2026.

Financial Strength and Governance Refresh

The robust financial performance demonstrates the company's success in growing revenue and profit in a competitive market, signaling positive momentum for shareholders. Appointing Deloitte as the new auditor marks a refresh in corporate governance, aligning with regulatory standards for the coming years. The declared dividend offers shareholders a direct return on their investment, though an upcoming ITAT hearing concerning tax demands introduces a point of uncertainty.

Company Context

Metropolis Healthcare has a history of consistent growth, driven by network expansion and increasing demand for diagnostic services in India, underpinning its current results. BSR & Co. LLP had served as the company's statutory auditor for several years. The company has previously dealt with tax demands and litigation, appearing before appellate authorities like the Income Tax Appellate Tribunal (ITAT), making the upcoming hearing significant.

Key Risks to Monitor

The main risk centers on the outcome of the ITAT hearing scheduled for May 14, 2026, related to tax demands from the Income Tax Department. An adverse ruling could result in financial penalties or additional liabilities, affecting profitability and cash flows. The change in statutory auditors warrants monitoring for any specific observations or concerns Deloitte may raise in future reports.

Competitive Landscape

With FY26 revenue growth around 22% and profit growth of 31%, Metropolis Healthcare is positioned competitively. Rivals include Dr. Lal PathLabs, focused on network expansion and service diversification; Thyrocare Technologies, leveraging its cost-efficient model; and Vijaya Diagnostic Centre, known for its strong regional presence.

Financial Metrics

• Consolidated Revenue: ₹1,645.85 crore for FY2026 vs ₹1,346.32 crore for FY2025.
• Consolidated Profit After Tax: ₹190.02 crore for FY2026 vs ₹145.51 crore for FY2025.
• Standalone Revenue: ₹1,381.80 crore for FY2026 vs ₹1,232.80 crore for FY2025.
• Standalone Profit After Tax: ₹157.14 crore for FY2026 vs ₹124.34 crore for FY2025.

Investor Watchlist

Shareholders should watch for formal approval of Deloitte Haskins & Sells as statutory auditors at the upcoming 26th Annual General Meeting (AGM). The ITAT hearing outcome on May 14, 2026, regarding the Income Tax Department's demands, remains a critical factor for financial risk assessment. Completion of the interim dividend payment, expected by June 12, 2026, will be a point to track. Future quarterly results will indicate the continuation of revenue and profit growth trends.